<i>M. avium Complex</i> Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development
Worldwide, several million people are infected with mycobacteria such as <i>Mycobacterium tuberculosis</i> (<i>M. tb</i>) or non-tuberculous mycobacteria (NTM). In 2023, 10.8 million cases and 1.25 million deaths due to <i>M. tb</i> were recorded. In Europe and No...
Saved in:
| Main Authors: | Elise Si Ahmed Charrier, Alexandra Dassonville-Klimpt, Claire Andréjak, Pascal Sonnet |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/6/891 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antimicrobial resistance of Mycobacterium avium during the COVID-19 pandemic
by: Vasilyeva I.A., et al.
Published: (2024-12-01) -
Comparative efficacy of tetracyclines against isolates of Mycobacterium avium complex
by: S. Singh, et al.
Published: (2025-02-01) -
Non-tuberculous mycobacteria in phthisiopulmonary practice in the Republic of Uzbekistan
by: N. N. Parpieva, et al.
Published: (2021-05-01) -
Challenges in achieving the guideline-recommended amikacin level for Mycobacterium avium complex pulmonary disease
by: Takuya Akutsu, et al.
Published: (2025-05-01) -
Non-Tuberculous Mycobacteria: Single Center Analyses of Risk Factors, Management and Mortality Outcomes of Adults with HIV
by: Lamla Nqwata, et al.
Published: (2024-11-01)